SXTP Stock Forecast & Price Target

60 Degrees is a specialty pharmaceutical company with a promising pipeline of therapies for infectious diseases, including recently reported positive results in the expanded-access study for Babesiosis and enrollment of the first patient in the chronic Babesiosis Phase II study. The recent 1:4 reverse stock split and $2.5 million ATM raise provide needed cash to support the company's operations in the next 3-6 months. These developments, along with partnerships with GoodRx and Runway Health to broaden patient access, position 60 Degrees for potential revenue growth and expansion into new indications. However, risks including regulatory approvals, financing needs, and competition should be considered in assessing the company's future prospects.

60 Degrees is currently facing challenges with commercializing their main product ARAKODA, despite solid progress in Q4 FY25 and success in their clinical data trials for Tafenoquine in babesiosis. However, these trials are still in early stages and the company's success is uncertain. Additionally, there is a potential for dilution from financing and low visibility on regulatory approval for new indications, leading to a negative outlook and an adjusted price target of $2.80 on higher share count.